Among the 196 DLBCL patients, mutations of the PIM1 gene were detected in 53 cases (27.04 %),MLL2 in 38 (18.39 %), FAT4 in 34 (15.9 %), TP53 in 29 (14.80 %), CD79B in 29 (14.80 %), MYD88 in 27 (13.78 %), PKD1 in 19 (9.69 %), CARD11 in 17 (8.67%), β2M in 16 (8.16 %), TNFAIP3 in 14 (7.14 %), CIITA in 14 (7.14 %), IRF4 in 12 (6.12 %), MYC in 11 (5.61 %), BCL-6 in 11 (5.61 %), CD58 in 10 (5.10%) and EP300 in 10 (5.10%). Here, CD58 is linked to diffuse large B-cell lymphoma.